去纤维钠在医保报销范围内吗？

Defibrotide is a single-stranded oligonucleotide mixture with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that Defibrotide is a safe and effective drug for preventing and treating hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). The U.S. FDA approved Defibrotide on March 30, 2016, for the treatment of severe hepatic veno-occlusive disease in adults and children after hematopoietic stem cell transplantation (usually complicated by renal and pulmonary function abnormalities). This is the first drug approved by the FDA for the treatment of severe hepatic veno-occlusive disease.

In 2000, a European research group (including 19 treatment centers) reported the efficacy of Defibrotide in 40 patients with HVOD, 28 of whom were patients with severe HVOD or multiple organ failure. The dosage of Defibrotide is 10~40 mg/kg/d, the median application time is 18 (2-71) days, and the median time of starting medication is +14 (-2+53) days after transplantation. The results showed that 22 cases had complete remission and 17 cases survived +100 days.

In 2002, a multi-center collaborative group in the United States reported the results of using Defibrotide in 87 patients with severe HVOD and multiple organ failure after hematopoietic stem cell transplantation. The dosage was 5-60 mg/kg/d, and the median treatment time was 15 days. As a result, 36% of the patients were completely relieved, and 35% of the patients survived the transplant. 100 days, and both studies showed that Defibrotide had no obvious side effects and was a safe and effective drug for the treatment of HVOD.

Defibrotide can be administered both intravenously and orally, with the recommended dose for adult and pediatric patients being 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue Defibrotide until resolution of VOD or up to a maximum of 60 days. Defibrotide must be diluted prior to infusion.

Is it covered by medical insurance reimbursement? Since Defibrotide has not yet been approved for marketing in China, patients currently cannot buy this drug in China, so Defibrotide cannot be included in medical insurance. Fortunately, patients can obtain their overseas drug purchase channels through reliable overseas medical service organizations in China (such as Medical Companion Travel).

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: